Last updated at 05 Jul 2024 05:57 PM
Director
DIN: 03433485
Archit Virmani is currently associated with 2 companies as Director. They serve as a Director at ZANEKA HEALTHCARE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 03433485.Archit Virmani has previously been associated with 1 company in roles such as Director and Additional Director.Archit Virmani is currently involved in 1 different role. Their most recent position is with DEVBHUMI PHARMACEUTICAL ANALYTICAL TESTING AND TRAINING FOUNDATION as a Director. The first company Archit Virmani was appointed to as a director was ZANEKA HEALTHCARE LIMITED. Archit Virmani is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Archit Virmani is currently associated with 2 companies as Director. They serve as a Director at ZANEKA HEALTHCARE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 03433485.Archit Virmani has previously been associated with 1 company in roles such as Director and Additional Director.Archit Virmani is currently involved in 1 different role. Their most recent position is with DEVBHUMI PHARMACEUTICAL ANALYTICAL TESTING AND TRAINING FOUNDATION as a Director. The first company Archit Virmani was appointed to as a director was ZANEKA HEALTHCARE LIMITED. Archit Virmani is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (1)
2y 9m 1y 5m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| ZANEKA HEALTHCARE LIMITED | Director | 31-Dec-2020 |
| DEVBHUMI PHARMACEUTICAL ANALYTICAL TESTING AND TRAINING FOUNDATION | Director | 29-Mar-2023 |